Business Wire

HOUSE-WELLNESS-FOODS

30.3.2021 12:32:10 CEST | Business Wire | Press release

Share
Study Shows House Wellness Foods’ Breakthrough Feed LP20® Can Advance the Potential of Rivers and Seas to Feed Our Emerging World

Vietnam is a nation that has seen its share of turmoil and suffering over the past century, and emerged from it with strength, enthusiasm, dedicated to progress and self-sufficiency. Over the past 50 years its participation on the global stage has steadily risen, with ever-increased attention to commerce, health, and education.

A recently released study on the efficacy of House Wellness Foods’ Feed LP20® in combating piscine disease factors can be seen as a glimmer of light along the pathway to Vietnam’s bright future.

As much as 35% of Vietnam’s aquacultural activity is built around river farming of the juvenile striped catfish [Pangasianodon hypophthalmus ] , making it the world’s largest producer of this nutritious staple, not only for its own consumption but for export to China, Europe, and elsewhere.

Vietnam’s story is one of many that expose the dual edge of farming to emerging populations. It’s been the keystone of civilization’s advancement since the dawn of humankind, but where resources are limited and need is great, farming’s potential hazards become viciously clear. Overstocked waters turn hazardous to human life due to excessive waste production and a rise in bacteria, parasites, fungi, and viruses. Overstocked waters produce fish that are increasingly malnourished, enervated, injured, and unable to reproduce.

The reflex response to this blight has been the use of antibiotics to keep weakened fish populations alive. Apart from expense, before long, disease-inducing agents mutate to resist the antibiotic, which, in turn, leads to the use of more varied antibiotics, causing a dangerous downward spiral . All the while antibiotics are entering the food chain and turning up in the human metabolic system to unpredictable, deleterious effect. Promise quickly turns to peril for the farmer, for the consumer, and for the future of vital aquaculture.

Feed LP20® can reverse this tide…

The details of this new study show its dramatic impact. In summary, researchers fed test stocks a diet supplemented with heat-killed Lactobacillus plantarum , strain L-137, the active ingredient in Feed LP20® . Key to the high effectiveness of Feed LP20® is the heat-killing process. It fully utilizes the strain’s characteristics, an area where House Wellness Foods holds an unparalleled position of authority based upon years of peer-reviewed testing and research, and continuous refinement of the development process. Heat treatment hardens bacillary cell walls and fixes their genetic material. Not only does this enable HK-L137 to resist initial breakdown in the upper gastric system, but it can be cooked, processed, stored, and administered in an aquatic environment without compromising potency. Further, both its ability to stimulate immune cytokine interleukin 12 and its shelf life far surpass that of any living lactobacillus supplement.

House Wellness Foods and the introduction of immunobiotics

Immunobiotics promote health by triggering immune responses in the mucosa. House Wellness Foods , one of Japan’s most trusted names in food production, began its exploration of immunobiotics and their ability to bolster human immune response, support liver function, and ameliorate the causes of chronic disease over three decades ago, and the culmination of their intensive research and meticulous development was their flagship Immuno-LP20® , with its active component of 20% heat-treated Lactobacillus plantarum L-137 (HK-L137). This potent lactobacillus follows a dual course on assimilation. It initiates production of signal molecule IL-12 and IFN-β cells — the latter being the most important single cytokine responsible for inhibiting viral multiplication; and it subsequently stimulates T cell activity and the production of both NK and cytotoxic T (CTL) effector cells, boosting innate immunity and fostering antibody creation as an adjunct to the adaptive immune response.

House followed the worldwide success of Immuno-LP20® , with the development of Feed LP20® , an alternative to antibiotics, and to the costly, unreliable, and lengthy process of cultivating disease-resistant strains of livestock. The overarching principle of immunobiotic therapy in both land-based and aquatic livestock is that the power to fight disease already exists within every living cell of the organism. Prior to the present study, Feed LP20® proved its remarkable effectiveness in other aquatic stock, including white leg shrimp and Nile tilapia . It recently began marketing in the EU as a complementary feed for poultry, swine, and salmonid.

The proof is in the food chain

The study shows that juvenile striped catfish fed HK-L137-supplemented diets exhibited higher final weight and specific growth rate than controlled stock given ordinary feed. The fish showed higher survival rate, longer life, better feed conversion ratios, weight gain, better protein efficiency ratios, and increased reproductive capacity. Further, a test sub-group was administered a bacterial challenge mirroring a real-life scenario in Vietnamese river farms of their most devastating bacterial threat, Bacillary Necrosis Disease (BNP), caused by the bacterial agent Edwardsiella ictaluri . Part of the test group was injected with this agent, and in every case the cumulative mortality of HK L-137-supplemented groups was lower than the group fed control diet.

Fitter fish, more successful farming, greater financial stability — all of this originating from the power of Feed LP20® , comprising 20% HK-L137 , to sustain health through enhanced immunity at the very cellular level. The new study shows the promise of House Wellness Foods’ Breakthrough Feed LP20®, and points to the future of a shared world that is often fragile, yet always filled with hope.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye